Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-2575 in mild-to-moderate systemic lupus erythematosus
NCT06182969Phase 2Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Aug 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in systemic lupus erythematosus (SLE), sponsored by Ascentage Pharma. Started Aug 2024; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06182969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182969.